These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 30350349)

  • 1. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
    Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
    Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of FOXE3 transcription factor as a potent oncogenic factor in triple-negative breast cancer.
    Wang H; Yang T; Yuan Y; Sun X
    Biochem Biophys Res Commun; 2020 Feb; 523(1):78-85. PubMed ID: 31831170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53.
    Yang M; Dang X; Tan Y; Wang M; Li X; Li G
    Biomed Pharmacother; 2018 Mar; 99():220-226. PubMed ID: 29334665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of cancerous progression by LISCH7 via direct stimulation of TGFB1 transcription in triple-negative breast cancer.
    Tang X; Zhou Y; Liu Y; Zhang W; Liu C; Yan C
    J Cell Biochem; 2020 Nov; 121(11):4642-4653. PubMed ID: 32048750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
    Synnott NC; O'Connell D; Crown J; Duffy MJ
    Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
    Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
    Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
    Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
    Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
    Morrison CD; Allington TM; Thompson CL; Gilmore HL; Chang JC; Keri RA; Schiemann WP
    Oncotarget; 2016 Nov; 7(45):72777-72794. PubMed ID: 27626309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM4 is a rational target for treating breast cancers with mutant p53.
    Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
    J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation.
    Chen T; Wang X; Li C; Zhang H; Liu Y; Han D; Li Y; Li Z; Luo D; Zhang N; Zheng M; Chen B; Wang L; Zhao W; Yang Q
    Oncogene; 2021 Apr; 40(15):2756-2771. PubMed ID: 33714984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circular RNA circPTK2 modulates migration and invasion via miR-136/NFIB signaling on triple-negative breast cancer cells in vitro.
    Wang M; Chen D; Zhang H; Luo C
    Inflamm Res; 2022 Apr; 71(4):409-421. PubMed ID: 35234989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-κB pathway in breast cancer cells.
    Huang P; Ouyang DJ; Chang S; Li MY; Li L; Li QY; Zeng R; Zou QY; Su J; Zhao P; Pei L; Yi WJ
    Cell Commun Signal; 2018 Nov; 16(1):92. PubMed ID: 30497491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer.
    Zhu A; Li Y; Song W; Xu Y; Yang F; Zhang W; Yin Y; Guan X
    Cell Physiol Biochem; 2016; 38(3):1003-14. PubMed ID: 26938985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
    Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
    Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.